CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues
Total revenues	$ 4,165,706	$ 1,616,141
Total cost of product and clinical laboratory service revenues	3,056,568	515,781
Gross profit	1,109,138	1,100,360
Operating expenses:
Selling, general and administrative	4,662,173	3,309,654
Research and development	1,080,096	763,808
Total operating expenses	5,742,269	4,073,462
LOSS FROM OPERATIONS	(4,633,131)	(2,973,102)
Other (expense) income:
Interest income (expense), net	273	(5,438)
Loss on extinguishment of debt	0	(1,774,662)
Other expense, net	(88,053)	(53,860)
Loss before provision for income taxes	(4,720,911)	(4,807,062)
Provision for income taxes	0	0
NET LOSS	(4,720,911)	(4,807,062)
Less: Net income attributable to noncontrolling interest	(855)	(2,494)
NET LOSS attributable to common stockholders	$ (4,721,766)	$ (4,809,556)
Net loss per share attributable to common stockholders - basic	$ (0.63)	$ (0.88)
Net loss per share attributable to common stockholders - diluted	$ (0.63)	$ (0.88)
Weighted average shares outstanding - basic	7,486,120	5,457,967
Weighted average shares outstanding - diluted	7,486,120	5,457,967
Product revenues
Revenues
Total revenues	$ 826,311	$ 550,097
Total cost of product and clinical laboratory service revenues	434,929	270,688
Service revenues
Revenues
Total revenues	139,273	293,274
Clinical laboratory service revenues
Revenues
Total revenues	3,200,122	772,770
Total cost of product and clinical laboratory service revenues	$ 2,621,639	$ 245,093